Want to see BRKR full AI Analyst Report?
Top Page
Bruker
(NASDAQ:BRKR)
Select Model
Select Model
Rating:62Neutral
Price Target:
$60.00
▼(-0.74% Downside)
Action:Reiterated
Date:08/04/26
BRKR scores 62 primarily due to mixed financial performance: revenue and cash flow are resilient and leverage is workable, but profitability has deteriorated into losses and margins have compressed. Technicals are supportive with a clear uptrend and positive momentum, though short-term momentum looks stretched. Valuation provides limited support given the negative P/E and minimal dividend yield, while the latest earnings call improves the outlook via maintained guidance, margin expansion expectations, and cost-savings progress despite impairment and regional/timing headwinds.
Positive Factors
Bookings & Backlog Health
Sustained strong bookings and a book-to-bill above 1 across quarters signal durable end-market demand and backlog visibility. This supports multi-quarter revenue conversion, reduces near-term demand volatility, and underpins capacity planning and future margin leverage as orders convert to sales.
Negative Factors
Goodwill Impairment & GAAP Loss
A $135M goodwill write‑down reflects prior acquisition underperformance (automation/spatial biology), reducing reported equity and GAAP earnings capacity. Impairments erode acquisition optionality, raise scrutiny on past M&A discipline, and can pressure investor confidence and capital allocation flexibility over a medium horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Bookings & Backlog Health
Sustained strong bookings and a book-to-bill above 1 across quarters signal durable end-market demand and backlog visibility. This supports multi-quarter revenue conversion, reduces near-term demand volatility, and underpins capacity planning and future margin leverage as orders convert to sales.
Read all positive factors
Bruker Key Performance Indicators (KPIs)
Any
Revenue by Geography
Shows where Bruker earns sales across regions, highlighting which markets drive growth and how diversified the company is. Reveals exposure to regional economic slowdowns, currency swings, and localized demand for scientific instruments and services.
Shows where Bruker earns sales across regions, highlighting which markets drive growth and how diversified the company is. Reveals exposure to regional economic slowdowns, currency swings, and localized demand for scientific instruments and services.
Data provided by:
The Fly
The FlyBruker (BRKR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.83B
Dividend Yield0.35%
Average Volume (3M)1.93M
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth1.65%
EPS Growth-233.85%
CountryUS
Employees11,085
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.70
Shares Outstanding152,359,310
10 Day Avg. Volume1,792,076
30 Day Avg. Volume1,933,707
Financial Highlights & Ratios
PEG Ratio2.62
Price to Book (P/B)2.91
Price to Sales (P/S)2.08
P/FCF Ratio514.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$56.00Price Target Upside-7.36% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)2.12
Revenue Forecast (FY)$3.56B
Bruker Business Overview & Revenue Model
Company Description
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segme...
How the Company Makes Money
Bruker primarily makes money by selling high-performance scientific instruments and related solutions to academic institutions, pharmaceutical and biotechnology companies, industrial manufacturers, and clinical/diagnostic customers. Its revenue mo...
Bruker Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call showed material operational and financial progress — notably a return to organic growth in Q2, substantial margin expansion, double-digit non-GAAP EPS growth, strong deep-tech and semiconductor bookings, and confirmed cost-savings execution and year guidance. However, material lowlights included a $135M goodwill impairment leading to a GAAP loss, lingering weakness in U.S. academic/government spending, regional softness in China and APAC, timing-related revenue recognition delays from longer lead-time deep tech orders, and FX/tariff headwinds. On balance the positive momentum in bookings, margins, cash flow and cost savings, along with maintained FY guidance, outweigh the notable one-time impairment and near-term timing/currency headwinds.Positive Updates
Returned to Organic Revenue Growth in Q2
Reported Q2 2026 revenue of $838.5M, up 5.2% year-over-year; organic revenue growth of 2.8% in Q2 (3.4% excluding U.S. tariff refunds). Acquisitions contributed 1.5% to revenue and constant currency growth was 4.3%.
Negative Updates
GAAP Loss from Large Goodwill Impairment
GAAP diluted loss per share of $0.41 in Q2 versus GAAP EPS of $0.05 in Q2 2025, driven primarily by a noncash goodwill impairment charge of $135M related to automation and spatial biology businesses that continue to incur operating losses.
Read all updates
Q2-2026 Updates
Positive
Negative
Returned to Organic Revenue Growth in Q2
Reported Q2 2026 revenue of $838.5M, up 5.2% year-over-year; organic revenue growth of 2.8% in Q2 (3.4% excluding U.S. tariff refunds). Acquisitions contributed 1.5% to revenue and constant currency growth was 4.3%.
Read all positive updates
Company Guidance
Bruker reiterated FY‑2026 guidance of $3.54–$3.57 billion in revenues (reported growth 3%–4%), with organic growth of 1%–2% and M&A contributing ~1.5%; foreign exchange is now a ~0.5% revenue tailwind (vs. prior 1.5%), and the company still expects non‑GAAP operating margin expansion of 250–300 basis points year‑over‑year and non‑GAAP EPS of $2.10–$2.15 (roughly +15%–17% vs. FY‑2025) after factoring a higher effective tax rate. Management said it remains on track for $140 million of annualized cost savings in 2026 (with an additional ~$20 million of savings expected from the new operating structure in 2027), noted net leverage was 2.8x at 6/30/26, and disclosed a ~ $20 million Q3→Q4 revenue timing shift that leaves Q3 organic revenue roughly flat to slightly up (with a slight sequential margin/EPS dip) and sets up a meaningful sequential and year‑over‑year improvement in Q4 (management indicated Q4 could be around the ~$1 billion level); guidance reflects FX and tax assumptions as of June 30, 2026 and incorporates the earlier‑than‑expected U.S. tariff refunds that added ~200 bps to Q2 operating margin and about $0.06 to Q2 EPS.Bruker Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
63
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.50B | 3.44B | 3.37B | 2.96B | 2.53B | 2.42B |
| Gross Profit | 1.63B | 1.58B | 1.65B | 1.51B | 1.31B | 1.21B |
| EBITDA | 247.70M | 302.60M | 438.60M | 675.50M | 518.70M | 497.10M |
| Net Income | -71.20M | -8.60M | 113.10M | 427.20M | 296.60M | 277.10M |
Balance Sheet | ||||||
| Total Assets | 6.05B | 6.24B | 5.81B | 4.25B | 3.61B | 3.65B |
| Cash, Cash Equivalents and Short-Term Investments | 184.90M | 298.80M | 183.40M | 488.30M | 645.50M | 1.17B |
| Total Debt | 1.92B | 2.04B | 2.25B | 1.38B | 1.27B | 1.39B |
| Total Liabilities | 3.63B | 3.73B | 3.99B | 2.84B | 2.48B | 2.57B |
| Stockholders Equity | 2.40B | 2.46B | 1.78B | 1.38B | 1.11B | 1.07B |
Cash Flow | ||||||
| Free Cash Flow | 93.90M | 13.90M | 136.00M | 243.20M | 145.20M | 190.40M |
| Operating Cash Flow | 190.40M | 134.10M | 251.30M | 350.10M | 274.40M | 282.40M |
| Investing Cash Flow | -144.30M | -196.50M | -1.76B | -326.00M | -251.60M | -192.40M |
| Financing Cash Flow | 35.10M | 135.10M | 1.23B | -193.40M | -415.30M | 318.70M |
Bruker Technical Analysis
Positive
60.45
Price Trends
58.31
Negative
49.88
Positive
46.60
Positive
Market Momentum
-0.40
Positive
49.77
Neutral
68.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Positive. The current price of 60.45 is above the 20-day moving average (MA) of 58.54, above the 50-day MA of 58.31, and above the 200-day MA of 46.60, indicating a neutral trend. The MACD of -0.40 indicates Positive momentum. The RSI at 49.77 is Neutral, neither overbought nor oversold. The STOCH value of 68.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRKR.
Bruker Risk Analysis
Bruker disclosed 42 risk factors in its most recent earnings report. Bruker reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bruker Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $11.54B | 21.64 | 11.59% | ― | 19.74% | 51.10% | |
70 Outperform | $9.75B | 42.77 | 3.15% | ― | 1.37% | -29.25% | |
69 Neutral | $4.53B | 23.83 | 15.41% | ― | 12.39% | ― | |
64 Neutral | $4.25B | 33.95 | 7.43% | ― | 2.62% | 53.15% | |
62 Neutral | $8.83B | -82.55 | -2.92% | 0.33% | 1.65% | -233.85% | |
61 Neutral | $11.17B | -56.78 | -27.07% | ― | 41.55% | -96.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
BRKR
Bruker
57.70
23.63
69.35%
BIO
Bio-Rad Laboratories
356.26
71.61
25.16%
ITGR
Integer Holdings
125.26
19.72
18.68%
GMED
Globus Medical
85.90
25.65
42.57%
GKOS
Glaukos
184.53
95.01
106.13%
LIVN
LivaNova
82.22
28.95
54.35%
Bruker Corporate Events
Business Operations and StrategyDividends
Bruker Declares Quarterly Dividend on Mandatory Convertible Preferred
Positive
Jul 30, 2026
On July 30, 2026, Bruker Corporation’s Board of Directors declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A, with a par value of $0.01 per share. The dividend is scheduled t...
Executive/Board ChangesShareholder Meetings
Bruker Shareholders Reelect Directors and Approve Governance Items
Positive
May 21, 2026
At its 2026 Annual Meeting of Stockholders held on May 21, 2026, Bruker Corporation’s shareholders elected Laura A. Francis, John J. (Jack) Phillips and Hermann F. Requardt, Ph.D. as Class II directors to serve three-year terms ending at the...
Dividends
Bruker Declares Quarterly Cash Dividend, Signaling Ongoing Confidence
Positive
May 15, 2026
On May 14, 2026, Bruker Corporation’s board of directors declared a quarterly cash dividend of $0.05 per share on its common stock, with a par value of $0.01 per share. The dividend is scheduled to be paid on July 7, 2026, to shareholders of...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.